FDA’s Focus on Devices Impacting Women’s Health is Fully Underway: Breast Implant Advisory Set for March 25-26

King & Spalding
Contact

Late last year, the Food and Drug Administration’s (FDA’s) Device Center announced a new objective when it comes to devices – “ensuring that the FDA is consistently first among the world’s regulatory agencies to identify and act upon safety signals related to medical devices.”[i]  With that objective in mind, FDA stated that it would focus on devices that impact women’s health.[ii]  It appears that this focus is already underway.  FDA held an advisory committee meeting February 12, 2019, concerning the safety and effectiveness of surgical mesh placed transvaginally in the anterior vaginal compartment to treat pelvic organ prolapse.[iii]   In addition, on February 15, 2019, FDA formally announced that it will hold an advisory committee meeting to address potential risks associated with breast implants on March 25 and 26, 2019.[iv]

FDA’s recent attention to device products impacting women comes amidst a surge of media attention around the process by which the agency approves drugs and medical devices.  For example, a report by the International Consortium of Investigative Journalists (ICIJ), the Implant Files, released last fall, devoted an entire segment to uncovering serious adverse events and suspected risks associated with breast implants— including an increased risk of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), an emerging type of lymphatic cancer. [v]

The focus on women’s health issues is unsurprising, if not overdue, given the growing national awareness of the need for more attention, research, and understanding, with regard to the unique health concerns of women.  Indeed, recent data suggest the United States is well behind other western nations when it comes to overall women’s health, and the gap is growing.[vi]

Below, we provide an overview of the focus and the genesis of the upcoming breast implant advisory committee meeting on March 25-26, as well as “key takeaways” regarding what FDA’s new focus on device safety and women’s health means for industry stakeholders.

Overview of Re-emerging Safety Concerns Associated with Breast Implants and UPcoming ADvIsory committee Meeting

Breaking protocol, on January 28, 2019, FDA Commissioner Gottlieb announced via Tweet that FDA would hold an advisory committee meeting on safety issues associated with breast implants.[vii]  The advisory committee meeting will be held on March 25-26, 2019.  Since Commissioner Gottlieb’s Tweet, FDA has issued a formal notice regarding the upcoming meeting, pursuant to the usual protocol, in the Federal Register.  The Federal Register notice provides that the advisory committee will focus on discussing and making recommendations regarding the benefits and risks of breast implants indicated for breast augmentation and reconstruction concerning the following topics:  (1) BIA-ALCL, (2) systemic symptoms reported in patients receiving breast implants, (3) the use of registries for breast implant surveillance, (4) magnetic resonance imaging screening for silent rupture of silicone gel-filled breast implants, (5) the use of surgical mesh in breast procedures such as breast reconstruction and mastopexy, (6) the use of real-world data and patient perspectives in regulatory decision making, and (7) best practices for informed consent discussions between patients and clinicians.[viii]

FDA first signaled its intention to hold this advisory committee meeting in a September 14, 2018, press release issued by Dr. Binita Ashar, Director of Surgical Devices in FDA’s Center for Devices and Radiological Health, on behalf of the agency.[ix]  The press release expressed disagreement with a study published by MD Anderson, which purported to be the largest study of breast implant outcomes to date.[x]  The study concluded that silicone implants are associated with an increased risk of systemic harms, including cancers, connective tissue diseases, autoimmune diseases, and reproductive issues.[xi]

More specifically, the MD Anderson study analyzed data generated by large post-approval studies (LPAS) that were required by FDA, after the agency approved silicone gel-filled implants sponsored by two manufacturers— Allergan and Mentor Corp.— in 2006.[xii]  Prior to those approvals, there had been a moratorium on the use of silicone-filled breast implants in the United States since 1992, after concerns emerged about their use and the incidence of cancer, connective tissue disease, and autoimmune disease.[xiii] The moratorium was eventually lifted after the Institute of Medicine determined that there was no evidence to support an association between breast implants and systemic diseases.[xiv]

In FDA’s press release, Dr. Ashar urged the public and the healthcare community to view the study’s conclusions with caution due to “significant shortcomings with the study’s methodology.”[xv]  In an editorial that Dr. Ashar released, accompanying the press release, Dr. Ashar was more specific— stating that the MD Anderson study failed to account for “methodological differences between studies, inconsistencies in the data, differential loss to follow-up, confounding, and other potential sources of bias.”[xvi]  She also stated that the limitations of MD Anderson’s study “highlight the need for better post-market evidence generation, including active surveillance capabilities,”[xvii] and that, toward that end, FDA is engaged in efforts to develop breast implant registries and to establish, in partnership with others, the National Evaluation System for heath Technology (NEST).[xviii]

Given the deficiencies in the MD Anderson study, Dr. Ashar clarified in the FDA press release that “the agency continues to believe that the weight of the currently available scientific evidence does not conclusively demonstrate an association between breast implants and connective tissue diseases.”[xix] This conclusion is consistent with FDA’s prior analysis of those studies, which the agency communicated in a 2011 Safety Update.[xx]  In that update, based upon review of the LPAS studies, FDA stated that “[t]here is no apparent association between silicone gel-filled breast implants and connective tissue disease, breast cancer or reproductive problems.”[xxi]

Nonetheless, Dr. Ashar stated, in her editorial accompanying the press release, that patients who are considering breast implants should be aware that:

  • “Breast implants are not lifetime devices and the longer a patient has the implants, the more likely they are to experience local complications and adverse outcomes requiring breast implant removal.
  • Local complications and adverse outcomes include capsular contracture, reoperation, removal, and implant rupture. Many patients also experience breast pain, wrinkling, asymmetry, scarring, and infection.
  • Breast implants are associated with BIA-ALCL, a cancer of the immune system. While most patients with BIA-ALCL may be treated only with breast implant removal, some patients have required radiation therapy, chemotherapy or both, and some patients have even died from BIA-ALCL.
  • At the present time, there is not sufficient evidence to show an association between breast implants and rheumatologic or connective tissue diseases.”[xxii]

Dr. Ashar went on to state that FDA “remains committed to [a] thoughtful, scientific, transparent, public dialogue concerning breast implant safety and effectiveness,” and that the agency would hold an advisory committee meeting in 2019 to ensure that patients and health care professionals have “accurate, scientific information about breast implant safety and effectiveness.”[xxiii]

Key Takeaways

With FDA’s November 2018 announcement of its new objective— to be the first among regulatory agencies worldwide to identify and act upon safety signals associated with medical devices— we are witnessing a clear pendulum swing.  Indeed, in 2012, the Device Center announced a decidedly different goal— to ensure that devices were “first in the world” to market in the U.S.[xxiv]— and that goal was repeated frequently, and as recently as January 2018, in the Device Center’s 2018-2020 Strategic Priorities.[xxv]   This recent shift is clearly due to mounting pressure from media reports, like the Implant Files, as well as a recent AP report stating that during Dr. Jeffrey Shuren’s tenure as the Center Director (since January 2010), device “approvals” have tripled while “warning letters to device manufacturers about product safety and quality issues have fallen roughly 80 percent.”[xxvi]

This type of media scrutiny, regardless of whether it is warranted, often leads to high level finger-pointing, and it is clear that the Device Center is working hard to provide itself with cover.  Indeed, the tone of Dr. Ashar’s September 2018 press release was notably defensive.  The vast majority of the release was dedicated to enumerating FDA’s past efforts to monitor the safety and effectiveness of breast implants. 

As FDA endeavors to show its rigor regarding device safety, the agency is likely to demand more data from device sponsors in both the pre-market and post-market space.  Indeed, in the pre-market space, FDA has already telegraphed that it is exploring the legality of sunsetting the use of certain devices as predicates, to drive more devices from the 510(k) process to the de novo process; and in the post-market space, stakeholders are likely to see more demands for Section 522 post-market surveillance studies and more sophisticated uses of data analytics.  Industry stakeholders also should expect more advisory committee meetings regarding the safety of devices that have been scrutinized by the media and clear calls by FDA for additional warnings.  Although FDA’s actions in this space will likely affect a wide array of devices, FDA itself has stated that it is focusing on women’s health.  Accordingly, we expect that the agency’s activities in this space will disproportionately affect devices that impact women.

Longer term, manufacturers of medical devices (and pharmaceuticals), as well as healthcare professionals, can expect an explosion of gender-specific research and results.  More information will flow, not only from the Agency’s focus on women’s health, but also from a greater societal awareness of long-standing deficits in women’s health and healthcare.  The “me too” movement, while not a health movement per se, is giving strength to voices advocating for women’s health and human rights.  While it is tempting to assume that heightened agency scrutiny will expose manufacturers to more product liability risk, a broader focus on women’s health might just enhance the safety profile of many drugs and devices and decrease litigation risk. 

This potential for decreased litigation risk stems from the fact that many of the most common health issues faced disproportionately by women (e.g., chronic pain, autoimmune diseases, and migraines) are poorly understood compared to health issues that are more common in men.  New research and data may help illuminate the true causes of symptoms that have been blamed by default on medical devices.  For example, fibromyalgia has long been alleged to be linked to breast implants, but connective tissue diseases such as fibromyalgia have been understudied, and many clinicians are ill-prepared to address them.  In the absence of good science to explain a patient’s symptoms, it is often easier to blame the device.  Hopefully, increased study of women’s health will help illuminate the true underlying cause for many of the most noxious health problems women confront. 

[i] See U.S. Food & Drug Admin., Statement from FDA Commissioner Scott Gottlieb, M.D. and Jeff Shuren, M.D., Director of the Center for Devices and Radiological Health, on FDA’s updates to Medical Device Safety Action Plan to Enhance Post-Market Safety (Nov. 20, 2018), https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm626286.htm.
[ii] See id.
[iii] U.S. Food & Drug. Admin., Obstetrics and Gynecology Devices Panel of the Medical Devices Advisory Committee, Notice of Meeting; 83 Fed. Reg. 63516, 63516 (Dec. 10, 2018), https://www.federalregister.gov/documents/2018/12/10/2018-26626/obstetrics-and-gynecology-devices-panel-of-the-medical-devices-advisory-committee-notice-of-meeting.
[iv] U.S. Food & Drug Admin., General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee, Notice of Meeting (“Breast Implant Advisory Committee Meeting Notice”), 84 Fed. Reg. 4476, 4476 (Feb. 15, 2019). See also U.S. Food & Drug. Admin, Breast Implants, https://www.fda.gov/medicaldevices/productsandmedicalprocedures/implantsandprosthetics/breastimplants/default.htm (last visited Feb. 8, 2018).
[v] Sasha Chavkin, Breast Implant Injuries Kept Hidden as New Health Threats Surface, ICIJ—The Implant Files (Nov. 26, 2018), https://www.icij.org/investigations/implant-files/breast-implant-injuries-kept-hidden-as-new-health-threats-surface/.
[vi] See Munira Z. Gunja et al., What is the Status of Women’s Health and Health Care in the U.S. Compared to Ten Other Countries?, The Commonwealth Fund (Dec. 19, 2018), https://www.commonwealthfund.org/publications/issue-briefs/2018/dec/womens-health-us-compared-ten-other-countries.
[vii] Scott Gottlieb, Tweet Announcing March 25 -26 Meeting on Benefit-Risk Profile of Breast Implants (Jan, 28, 2019), https://twitter.com/SGottliebFDA/status/1089971948396969984 (last visited Feb. 8, 2019).
[viii] Breast Implant Advisory Committee Meeting Notice, at 4476.
[ix] See U.S. Food & Drug Admin., Statement from Binita Ashar, M.D., of FDA’s Center for Devices and Radiological Health on Agency’s Commitment to Studying Breast Implant Safety (“September 2018 Statement”) (Sept. 14, 2018), https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm620589.htm.
[x] See Christopher J. Coroneos, M.D. et al., U.S. FDA Breast Implant Postapproval Studies: Long term Outcomes in 99,993 Patients, 269 Annals of Surgery 30, 30 (official publication, Jan. 2019).
[xi] See id. at 32-34.
[xii] Id. at 30.
[xiii] Id.
[xiv] See Stuart Bondurant, et. al., Institute of Medicine (US) Committee on the Safety of Silicone Breast Implants, Nat’l Academy Press (1999), executive summary.
[xv] See September 2018 Statement.
[xvi] Binita S. Ashar, Assessing the Risks of Breast Implants and FDA’s Vision for the National Breast Implant Registry (“Ashar Editorial”), 269 Annals of Surgery 37, 37 (official publication, Jan. 2019).
[xvii] Id.
[xviii] Id.
[xix] See September 2018 Statement.
[xx] See U.S. Food & Drug Admin., FDA Update on the Safety of Silicone Gel-Filled Implants, at 7, 20-21 (June 2011), https://www.fda.gov/downloads/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/BreastImplants/UCM260090.pdf.
[xxi] Id.
[xxii] Ashar Editorial.
[xxiii] Id.
[xxiv] U.S. Food & Drug Admin., CDRH’s 2018-2020 Strategic Priorities:  Achieving Our Vision of Timely Patient Access to High-Quality, Safe and Effective Medical Devices, Jan. 2018, at 3 (citing the 2012 Vision Statement), https://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDRH/CDRHVisionandMission/UCM592693.pdf
[xxv] Id.  See also U.S. Food & Drug Admin., 2013 Strategic Priorities, FDA Center for Devices and Radiological Health, at 4, https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDRH/CDRHVisionandMission/default.htm  
[xxvi] Matthew Perrone, At FDA, a New Goal, Then a Push for Speedy Device Reviews, AP News (Nov. 27, 2018), https://www.apnews.com/9f8ea03a4d324d1ba5585680d280804b

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© King & Spalding | Attorney Advertising

Written by:

King & Spalding
Contact
more
less

King & Spalding on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide

JD Supra Privacy Policy

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at www.jdsupra.com) (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Collection of Information

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

  • Email
  • First Name
  • Last Name
  • Company Name
  • Company Industry
  • Title
  • Country

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

How do we use this information?

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

  • Operate our Website and Services and publish content;
  • Distribute content to you in accordance with your preferences as well as to provide other notifications to you (for example, updates about our policies and terms);
  • Measure readership and usage of the Website and Services;
  • Communicate with you regarding your questions and requests;
  • Authenticate users and to provide for the safety and security of our Website and Services;
  • Conduct research and similar activities to improve our Website and Services; and
  • Comply with our legal and regulatory responsibilities and to enforce our rights.

How is your information shared?

  • Content and other public information (such as an author profile) is shared on our Website and Services, including via email digests and social media feeds, and is accessible to the general public.
  • If you choose to use our Website and Services to communicate directly with a company or individual, such communication may be shared accordingly.
  • Readership information is provided to publishing law firms and authors of content to give them insight into their readership and to help them to improve their content.
  • Our Website may offer you the opportunity to share information through our Website, such as through Facebook's "Like" or Twitter's "Tweet" button. We offer this functionality to help generate interest in our Website and content and to permit you to recommend content to your contacts. You should be aware that sharing through such functionality may result in information being collected by the applicable social media network and possibly being made publicly available (for example, through a search engine). Any such information collection would be subject to such third party social media network's privacy policy.
  • Your information may also be shared to parties who support our business, such as professional advisors as well as web-hosting providers, analytics providers and other information technology providers.
  • Any court, governmental authority, law enforcement agency or other third party where we believe disclosure is necessary to comply with a legal or regulatory obligation, or otherwise to protect our rights, the rights of any third party or individuals' personal safety, or to detect, prevent, or otherwise address fraud, security or safety issues.
  • To our affiliated entities and in connection with the sale, assignment or other transfer of our company or our business.

How We Protect Your Information

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at privacy@jdsupra.com.

Children's Information

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Links to Other Websites

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

Information for EU and Swiss Residents

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

  • Our Legal Basis for Processing: Generally, we rely on our legitimate interests in order to process your personal information. For example, we rely on this legal ground if we use your personal information to manage your Registration Data and administer our relationship with you; to deliver our Website and Services; understand and improve our Website and Services; report reader analytics to our authors; to personalize your experience on our Website and Services; and where necessary to protect or defend our or another's rights or property, or to detect, prevent, or otherwise address fraud, security, safety or privacy issues. Please see Article 6(1)(f) of the E.U. General Data Protection Regulation ("GDPR") In addition, there may be other situations where other grounds for processing may exist, such as where processing is a result of legal requirements (GDPR Article 6(1)(c)) or for reasons of public interest (GDPR Article 6(1)(e)). Please see the "Your Rights" section of this Privacy Policy immediately below for more information about how you may request that we limit or refrain from processing your personal information.
  • Your Rights
    • Right of Access/Portability: You can ask to review details about the information we hold about you and how that information has been used and disclosed. Note that we may request to verify your identification before fulfilling your request. You can also request that your personal information is provided to you in a commonly used electronic format so that you can share it with other organizations.
    • Right to Correct Information: You may ask that we make corrections to any information we hold, if you believe such correction to be necessary.
    • Right to Restrict Our Processing or Erasure of Information: You also have the right in certain circumstances to ask us to restrict processing of your personal information or to erase your personal information. Where you have consented to our use of your personal information, you can withdraw your consent at any time.

You can make a request to exercise any of these rights by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

  • Timeframe for retaining your personal information: We will retain your personal information in a form that identifies you only for as long as it serves the purpose(s) for which it was initially collected as stated in this Privacy Policy, or subsequently authorized. We may continue processing your personal information for longer periods, but only for the time and to the extent such processing reasonably serves the purposes of archiving in the public interest, journalism, literature and art, scientific or historical research and statistical analysis, and subject to the protection of this Privacy Policy. For example, if you are an author, your personal information may continue to be published in connection with your article indefinitely. When we have no ongoing legitimate business need to process your personal information, we will either delete or anonymize it, or, if this is not possible (for example, because your personal information has been stored in backup archives), then we will securely store your personal information and isolate it from any further processing until deletion is possible.
  • Onward Transfer to Third Parties: As noted in the "How We Share Your Data" Section above, JD Supra may share your information with third parties. When JD Supra discloses your personal information to third parties, we have ensured that such third parties have either certified under the EU-U.S. or Swiss Privacy Shield Framework and will process all personal data received from EU member states/Switzerland in reliance on the applicable Privacy Shield Framework or that they have been subjected to strict contractual provisions in their contract with us to guarantee an adequate level of data protection for your data.

California Privacy Rights

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

Access/Correct/Update/Delete Personal Information

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to privacy@jdsupra.com. We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to privacy@jdsupra.com.

Changes in Our Privacy Policy

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

Contacting JD Supra

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at: privacy@jdsupra.com.

JD Supra Cookie Guide

As with many websites, JD Supra's website (located at www.jdsupra.com) (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

How We Use Cookies and Other Tracking Technologies

We use cookies and other tracking technologies to:

  1. Improve the user experience on our Website and Services;
  2. Store the authorization token that users receive when they login to the private areas of our Website. This token is specific to a user's login session and requires a valid username and password to obtain. It is required to access the user's profile information, subscriptions, and analytics;
  3. Track anonymous site usage; and
  4. Permit connectivity with social media networks to permit content sharing.

There are different types of cookies and other technologies used our Website, notably:

  • "Session cookies" - These cookies only last as long as your online session, and disappear from your computer or device when you close your browser (like Internet Explorer, Google Chrome or Safari).
  • "Persistent cookies" - These cookies stay on your computer or device after your browser has been closed and last for a time specified in the cookie. We use persistent cookies when we need to know who you are for more than one browsing session. For example, we use them to remember your preferences for the next time you visit.
  • "Web Beacons/Pixels" - Some of our web pages and emails may also contain small electronic images known as web beacons, clear GIFs or single-pixel GIFs. These images are placed on a web page or email and typically work in conjunction with cookies to collect data. We use these images to identify our users and user behavior, such as counting the number of users who have visited a web page or acted upon one of our email digests.

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

  • HubSpot - For more information about HubSpot cookies, please visit legal.hubspot.com/privacy-policy.
  • New Relic - For more information on New Relic cookies, please visit www.newrelic.com/privacy.
  • Google Analytics - For more information on Google Analytics cookies, visit www.google.com/policies. To opt-out of being tracked by Google Analytics across all websites visit http://tools.google.com/dlpage/gaoptout. This will allow you to download and install a Google Analytics cookie-free web browser.

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

Controlling and Deleting Cookies

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit http://www.aboutcookies.org which explains, step-by-step, how to control and delete cookies in most browsers.

Updates to This Policy

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

Contacting JD Supra

If you have any questions about how we use cookies and other tracking technologies, please contact us at: privacy@jdsupra.com.

- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.